GWP
QNCX icon

Gen-Wealth Partners’s Quince Therapeutics QNCX Stock Holding History

Gen-Wealth Partners’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.35K Buy
+165
New +$33.1K ﹤0.01% 613

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Gen-Wealth Partners's QNCX Position: Q1 2026 in Review

Gen-Wealth Partners opened a new position in Quince Therapeutics (QNCX) in Q1 2026: 165 shares worth $3.35K. The stake represents ﹤0.01% of the portfolio and ranks #613 among its holdings.

43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Gen-Wealth Partners held 165 shares of Quince Therapeutics worth $3.35K as of Q1 2026.
  • Quince Therapeutics was a new Gen-Wealth Partners position in Q1 2026.
  • Quince Therapeutics made up ﹤0.01% of Gen-Wealth Partners's portfolio in Q1 2026, its #613 holding.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Gen-Wealth Partners's 13F filing for Q1 2026, filed 8 May 2026.